| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
57 |
| Employees |
71 |
| Revenues (TTM) (Millions $) |
167 |
| Net Income (TTM) (Millions $) |
-66 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Paratek Pharmaceuticals Inc is a US-based biopharmaceutical company that develops innovative therapies for the treatment of infectious diseases and other serious conditions. The company was founded in 1996 with a focus on developing antibiotics to address the growing problem of antibiotic-resistant bacteria.
The company's lead product is NUZYRA, a once-daily oral and intravenous antibiotic that is approved for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is unique in that it is effective against a wide range of bacteria, including those that are resistant to other antibiotics, such as MRSA.
In addition to NUZYRA, Paratek is also developing a second antibiotic, SEYSARA, for the treatment of acne vulgaris. SEYSARA is a once-daily oral antibiotic that targets a specific type of bacteria that is commonly associated with acne.
Paratek has a strong pipeline of additional antibiotics in development, including drugs targeting gram-negative bacteria, which are notoriously difficult to treat. The company's approach to drug development is focused on using innovative technologies and approaches to discover and develop drugs that are effective against drug-resistant bacteria.
Paratek has partnerships and collaborations with a number of academic and commercial organizations, including the US Department of Defense, which is funding the development of a new class of antibiotics for use in biodefense.
The company is headquartered in Boston, Massachusetts, and has additional offices in King of Prussia, Pennsylvania, and Zug, Switzerland. Paratek has a workforce of approximately 160 employees.
Overall, Paratek Pharmaceuticals is a pioneering biopharmaceutical company that is committed to developing innovative therapies for the treatment of infectious diseases and other serious conditions. With a strong pipeline of antibiotics in development and a focus on using cutting-edge technologies and approaches to drug discovery, Paratek is poised to make a significant impact on the field of antibiotic development and change the way we treat drug-resistant infections.
Company Address: 75 Park Plaza Boston 2116 MA
Company Phone Number: 807-6600 Stock Exchange / Ticker: NASDAQ PRTK
|
%
0.23%